BridgeBio Pharma (BBIO) said Monday acoramidis showed "statistically significant improvements" in clinical outcomes in both variant and wild-type transthyretin amyloid cardiomyopathy, or ATTR-CM, in a phase 3 trial.

The study compared acoramidis with placebo for time to all-cause mortality or first cardiovascular-related hospitalization in both variant and wild-type ATTR-CM, the company said.

Data showed that acoramidis increased serum transthyretin concentrations along with a 59.1% reduction in the risk of mortality or first hospitalization compared with placebo in patients with variant ATTR-CM, and 31.2% risk reduction in patients with wild-type ATTR-CM at month 30, according to the company.

Acoramidis also stabilized TTR levels in both patient groups, demonstrating over 90% stabilization, the company said.

Acoramidis is approved as Attruby in the US and as Beyonttra in the European Union and Japan.

Price: 34.62, Change: -0.49, Percent Change: -1.40